About us
Preventing infection at the source
Lindo Life Science develops antimicrobial technologies to support infection prevention at the source and improve patient outcomes in healthcare environments.
As part of the Lindo Technology Group, we combine scientific research, clinical insight and medical device development to address some of healthcare’s most persistent infection challenges.
Importantly, our work starts with a simple belief. Infection prevention should begin at the source. Therefore, we focus on preventative technologies that are effective, practical and designed for real world clinical use.
Our vision for the future
At Lindo Life Science, we dare to imagine a future where infection prevention is built into healthcare systems as a global standard to improve patient outcomes at scale and reduce reliance on treatment.
Currently, the global healthcare system manage infection after it occurs, relying on treatment, chemicals and labour-intensive processes that place growing pressure on patients, clinicians and infrastructure.
With Lindo Life Science, healthcare can make a category-defining shift toward prevention at the source through embedded, autonomous infection prevention systems designed for real-world clinical environments.
Early validation is secured
Lindo Life Science is advancing its medical device portfolio through a strong foundation of clinical collaboration, strategic partnerships and government support.
The business is supported by matched AU$2 million funding from the Australian Government’s Industry Growth Program and operates under a strategic know how licence agreement with Mayo Clinic, enabling close collaboration with clinicians in the United States.
Our broader partner network includes leading organisations across medical device design, engineering, regulatory strategy and translational research.
These partnerships allow us to move efficiently from scientific concept to clinically relevant solutions while maintaining a clear pathway toward regulatory approval and commercialisation.
Our investment partners & project collaborators
Built on proven technology
Part of the Lindo Technology Group, Lindo Life Science builds on years of antimicrobial blue light innovation developed across health-critical environments to reduce contamination in air, water and on surfaces.
The Life Science division was established to focus exclusively on developing regulated healthcare applications, medical device development and clinical collaboration
Today, Lindo Life Science represents the fastest growing area of the Lindo Group and a core pillar of its future direction.
Why invest now?
Redefining Healthcare Category
Lindo Life Science is positioned to capture a share of a US$100B+ global opportunity by shifting infection control from treatment to prevention at the source — with a clear pathway to commercialisation, early revenue and scalable growth.
Moving Towards Commercialisation
Lindo Life Science is advancing through a structured development pathway designed to validate technology, secure regulatory approval and enable commercial scale. We have a development timeline where each milestone reduces technical and market risk while positioning the platform for global deployment across healthcare systems.
Our technology has patents pending. It is grounded in established antimicrobial blue light research and supported by ongoing collaboration with academic and clinical partners. All of our solutions focus on mechanisms that reduce bacteria without contributing to antimicrobial resistance.
Non-Chemical, Always-On Disinfection
By using aBL technology, our approach avoids reliance on chemicals or antibiotics, offering an alternative pathway to bacterial reduction that supports broader antimicrobial stewardship goals.
Our disinfection lighting systems are autonomous, delivering continuous antimicrobial activity without reliance on human intervention or interrupting the flow of clinical care.
Versatile & Scalable
A single technology platform that is versatile and ready to apply across multiple infection risk points enabling significant impact at scale. Additionally, our solutions are "retro-fit-ready" and can be easily embedded inside existing drains, ventilators and infrastructure without requiring workflow change or system redesign.
Defensible IP Protection
A layered intellectual property strategy protects both the core technology and its application within healthcare systems. By combining owned patents, exclusive licensing and validated freedom to operate, Lindo creates a durable competitive advantage and a clear pathway to commercialisation at scale.
Industry & Government Validation
Government funding, clinical partnerships and industry collaboration demonstrate
strong external validation and readiness to scale.
Lindo Life Science has partnered with Mayo Clinic to develop an endotracheal tube embedded with aBL technology to reduce VAP and improve patient outcomes. This collaboration supports the advancement of a proof of concept, combining clinical expertise with Lindo’s innovation to target harmful bacteria in ventilator circuits.
The initiative is backed by $2 million in matched funding from the Australian Government’s Industry Growth Program, enabling progression toward clinical trials and commercial readiness. Supported by a consortium of partners, the project aims to scale globally while strengthening Australia’s medical device innovation and manufacturing capability.
Prevention at scale
Explore Lindo Life Science’s pathway to clinical validation, commercialisation and global healthcare impact.